Dual effect of the heart-targeting cytokine cardiotrophin-1 on glucose transport in cardiomyocytes

Journal of Molecular and Cellular Cardiology

Volumn 56, Issue 1, 2013, Pages 106-115

  Asrih, Mohamed ^a,b   Gardier, Stéphany ^a   Papageorgiou, Irène ^a,b   Montessuit, Christophe ^a,b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

Cardiomyocytes; Cardiotrophin 1; Glucose transport; Insulin resistance

Indexed keywords

CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CARDIOTROPHIN 1; CELL PROTEIN; GLUCOSE; GLUCOSE TRANSPORTER 4; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; N [2 [[N [3 (4 CHLOROPHENYL) 2 PROPENYL] N METHYLAMINO]METHYL]PHENYL] N (2 HYDROXYETHYL) 4 METHOXYBENZENESULFONAMIDE; OLIGOMYCIN; PROTEIN AS160; PROTEIN KINASE B; PYRUVATE DEHYDROGENASE; STAT5 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; UNCLASSIFIED DRUG;

ADULT ANIMAL; ANIMAL CELL; ARTICLE; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HEART MUSCLE CELL; INHIBITION KINETICS; MALE; METABOLIC STRESS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION;

ANIMALS; BIOLOGICAL TRANSPORT; CELL HYPOXIA; CELLS, CULTURED; CYTOKINES; GLUCOSE; GLUCOSE TRANSPORTER TYPE 1; GLUCOSE TRANSPORTER TYPE 4; INSULIN; MALE; MYOCYTES, CARDIAC; OLIGOMYCINS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PYRUVATE DEHYDROGENASE (LIPOAMIDE); RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; STRESS, PHYSIOLOGICAL;

EID: 84873189237     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2012.12.015     Document Type: Article

References (54)

1. Montessuit C. Regulation and dysregulation of glucose transport in cardiomyocytes. Biochim Biophys Acta 2013, 10.1016/j.bbamcr.2012.08.009.
2. Tian R., Abel E.D. Responses of GLUT4-deficient hearts to ischemia underscore the importance of glycolysis. Circulation 2001, 103:2961-2966.
3. Russell R.R., Li J., Coven D.L., Pypaert M., Zechner C., Palmeri M., et al. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J Clin Invest 2004, 114:495-503.
4. Donath M.Y., Shoelson S.E. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011, 11:98-107.
5. Natal C., Fortuno M.A., Restituto P., Bazan A., Colina I., Diez J., et al. Cardiotrophin-1 is expressed in adipose tissue and upregulated in the metabolic syndrome. Am J Physiol Endocrinol Metab 2008, 294:E52-E60.
6. Fischer P., Hilfiker-Kleiner D. Survival pathways in hypertrophy and heart failure: the gp130-STAT3 axis. Basic Res Cardiol 2007, 102:279-297.
7. Craig R., Wagner M., McCardle T., Craig A.G., Glembotski C.C. The cytoprotective effects of the glycoprotein 130 receptor-coupled cytokine, cardiotrophin-1, require activation of NF-κB. J Biol Chem 2001, 276:37621-37629.
8. Florholmen G., Thoresen G., Rustan A., Jensen J., Christensen G., Aas V. Leukaemia inhibitory factor stimulates glucose transport in isolated cardiomyocytes and induces insulin resistance after chronic exposure. Diabetologia 2006, 49:724-731.
9. Zvonic S., Hogan J.C., Arbour-Reily P., Mynatt R.L., Stephens J.M. Effects of cardiotrophin on adipocytes. J Biol Chem 2004, 279:47572-47579.
10. Moreno-Aliaga M.J., Pérez-Echarri N., Marcos-Gómez B., Larequi E., Gil-Bea F.J., Viollet B., et al. Cardiotrophin-1 is a key regulator of glucose and lipid metabolism. Cell Metab 2011, 14:242-253.
11. Asrih M., Pellieux C., Papageorgiou I., Lerch R., Montessuit C. Role of ERK1/2 activation in microtubule stabilization and glucose transport in cardiomyocytes. Am J Physiol Endocrinol Metab 2011, 301:E836-E843.
12. Claycomb W., Palazzo M. Culture of the terminally differentiated adult cardiac muscle cell: a light and scanning electron microscope study. Dev Biol 1980, 80:466-482.
13. Eppenberger-Eberhardt M., Flamme I., Kurer V., Eppenberger H.M. Reexpression of α-smooth muscle actin isoform in cultured adult rat cardiomyocytes. Dev Biol 1990, 139:269-278.
14. Rosenblatt-Velin N., Lerch R., Papageorgiou I., Montessuit C. Insulin resistance in adult cardiomyocytes undergoing dedifferentiation: role of GLUT4 expression and translocation. FASEB J 2004, 18:872-874.
15. Montessuit C., Papageorgiou I., Lerch R. Nuclear receptors agonists improve insulin responsiveness in cultured cardiomyocytes through enhanced signaling and preserved cytoskeletal architecture. Endocrinology 2008, 149:1064-1074.
16. Chen J., Sadowski H.B., Kohanski R.A., Wang L.-H. Stat5 is a physiological substrate of the insulin receptor. Proc Natl Acad Sci U S A 1997, 94:2295-2300.
17. Sadowski C.L., Choi T.-S., Le M., Wheeler T.T., Wang L.-H., Sadowski H.B. Insulin Induction of SOCS-2 and SOCS-3 mRNA Expression in C2C12 Skeletal Muscle Cells Is Mediated by Stat5. J Biol Chem 2001, 276:20703-20710.
18. Emanuelli B., Peraldi P., Filloux C., Sawka-Verhelle D., Hilton D., Van Obberghen E. SOCS-3 is an insulin-induced negative regulator of insulin signaling. J Biol Chem 2000, 275:15985-15991.
19. Davey H.W., McLachlan M.J., Wilkins R.J., Hilton D.J., Adams T.E. STAT5b mediates the GH-induced expression of SOCS-2 and SOCS-3 mRNA in the liver. Mol Cell Endocrinol 1999, 158:111-116.
20. Senn J.J., Klover P.J., Nowak I.A., Zimmers T.A., Koniaris L.G., Furlanetto R.W., et al. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem 2003, 278:13740-13746.
21. Lebrun P., Van Obberghen E. SOCS proteins causing trouble in insulin action. Acta Physiol 2008, 192:29-36.
22. Müller J., Sperl B., Reindl W., Kiessling A., Berg T. Discovery of chromone-based inhibitors of the transcription factor STAT5. Chembiochem 2008, 9:723-727.
23. Scheid M.P., Marignani P.A., Woodgett J.R. Multiple phosphoinositide 3-kinase-dependent steps in activation of protein kinase B. Mol Cell Biol 2002, 22:6247-6260.
24. Kane S., Sano H., Liu S.C.H., Asara J.M., Lane W.S., Garner C.C., et al. A method to identify serine kinase substrates. Akt phosphorylates a novel adipocyte protein with a Rab GTPase-activating protein (GAP) domain. J Biol Chem 2002, 277:22115-22118.
25. Sano H., Kane S., Sano E., Miinea C.P., Asara J.M., Lane W.S., et al. Insulin-stimulated phosphorylation of a Rab GTPase-activating protein regulates GLUT4 translocation. J Biol Chem 2003, 278:14599-14602.
26. Kramer H.F., Witczak C.A., Fujii N., Jessen N., Taylor E.B., Arnolds D.E., et al. Distinct signals regulate AS160 phosphorylation in response to insulin, AICAR, and contraction in mouse skeletal muscle. Diabetes 2006, 55:2067-2076.
27. Thong F.S.L., Bilan P.J., Klip A. The Rab GTPase-activating protein AS160 integrates Akt, protein kinase C, and AMP-activated protein kinase signals regulating GLUT4 traffic. Diabetes 2007, 56:414-423.
28. Sanders M.J., Grondin P.O., Hegarty B.D., Snowden M.A., Carling D. Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade. Biochem J 2007, 403:139-148.
29. Hawley S.A., Pan D.A., Mustard K.J., Ross L., Bain J., Edelman A.M., et al. Calmodulin-dependent protein kinase kinase-β is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab 2005, 2:9-19.
30. 2+/calmodulin-dependent protein kinase kinase-β acts upstream of AMP-activated protein kinase in mammalian cells. Cell Metab 2005, 2:21-33.
31. 2+-dependent signaling pathways regulating FA uptake and oxidation in contracting rodent muscle. J Appl Physiol 2008, 104:1366-1373.
32. Tokumitsu H., Inuzuka H., Ishikawa Y., Ikeda M., Saji I., Kobayashi R. STO-609, a specific inhibitor of the Ca2+/calmodulin-dependent protein kinase kinase. J Biol Chem 2002, 277:15813-15818.
33. 2+/calmodulin dependent protein kinase II inhibitor KN-93 reduces dopamine contents in PC12h cells. Biochem Biophys Res Commun 1991, 181:968-975.
34. Robador P.A., San José G., Rodríguez C., Guadall A., Moreno M.U., Beaumont J., et al. HIF-1-mediated up-regulation of cardiotrophin-1 is involved in the survival response of cardiomyocytes to hypoxia. Cardiovasc Res 2011, 92:247-255.
35. Mann W.R., Dragland C.J., Vinluan C.C., Vedananda T.R., Bell P.A., Aicher T.D. Diverse mechanisms of inhibition of pyruvate dehydrogenase kinase by structurally distinct inhibitors. Biochim Biophys Acta 2000, 1480:283-292.
36. Kato T., Sano M., Miyoshi S., Sato T., Hakuno D., Ishida H., et al. Calmodulin kinases II and IV and calcineurin are involved in leukemia inhibitory factor-induced cardiac hypertrophy in rats. Circ Res 2000, 87:937-945.
37. Fujio Y., Maeda M., Mohri T., Obana M., Iwakura T., Hayama A., et al. Glycoprotein 130 cytokine signal as a therapeutic target against cardiovascular diseases. J Pharmacol Sci 2011, 117:213-222.
38. Carey A.L., Steinberg G.R., Macaulay S.L., Thomas W.G., Holmes A.G., Ramm G., et al. Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes 2006, 55:2688-2697.
39. Steinberg G.R., Watt M.J., Ernst M., Birnbaum M.J., Kemp B.E., Jørgensen S.B. Ciliary neurotrophic factor stimulates muscle glucose uptake by a PI3-kinase-dependent pathway that is impaired with obesity. Diabetes 2009, 58:829-839.
40. Watt M.J., Dzamko N., Thomas W.G., Rose-John S., Ernst M., Carling D., et al. CNTF reverses obesity-induced insulin resistance by activating skeletal muscle AMPK. Nat Med 2006, 12:541-548.
41. Kaczmarczyk S.J., Andrikopoulos S., Favaloro J., Domenighetti A.A., Dunn A., Ernst M., et al. Threshold effects of glucose transporter-4 (GLUT4) deficiency on cardiac glucose uptake and development of hypertrophy. J Mol Endocrinol 2003, 31:449-459.
42. Calegari V.C., Alves M., Picardi P.K., Inoue R.Y., Franchini K.G., Saad M.J.A., et al. Suppressor of cytokine signaling-3 provides a novel interface in the cross-talk between angiotensin II and insulin signaling systems. Endocrinology 2005, 146:579-588.
43. Asrih M., Lerch R., Papageorgiou I., Pellieux C., Montessuit C. Differential regulation of stimulated glucose transport by free fatty acids and PPARα or δ agonists in cardiac myocytes. Am J Physiol Endocrinol Metab 2012, 302:E872-E884.
44. Bertrand L., Ginion A., Beauloye C., Hebert A.D., Guigas B., Hue L., et al. AMPK activation restores the stimulation of glucose uptake in an in vitro model of insulin-resistant cardiomyocytes via the activation of protein kinase B. Am J Physiol Heart Circ Physiol 2006, 291:H239-H250.
45. Chopra I., Li H.F., Wang H., Webster K.A. Phosphorylation of the insulin receptor by AMP-activated protein kinase (AMPK) promotes ligand-independent activation of the insulin signalling pathway in rodent muscle. Diabetologia 2012, 55:783-794.
46. Wright D.C., Fick C.A., Olesen J.B., Lim K., Barnes B.R., Craig B.W. A role for calcium/calmodulin kinase in insulin stimulated glucose transport. Life Sci 2004, 74:815-825.
47. 2+/calmodulin-dependent protein kinase II in L6 myotubes. Cell Signal 2012, 24:302-308.
48. Ojuka E.O., Goyaram V., Smith J.A.H. The role of CaMKII in regulating GLUT4 expression in skeletal muscle. Am J Physiol Endocrinol Metab 2012, 303:E322-E331.
49. Montessuit C., Rosenblatt-Velin N., Papageorgiou I., Campos L., Pellieux C., Palma T., et al. Regulation of glucose transporters expression in cardiac myocytes: p38 MAPK is a strong inductor of GLUT4. Cardiovasc Res 2004, 64:94-104.
50. Jaswal J.S., Keung W., Wang W., Ussher J.R., Lopaschuk G.D. Targeting fatty acid and carbohydrate oxidation - a novel therapeutic intervention in the ischemic and failing heart. Biochim Biophys Acta 2011, 1813:1333-1350.
51. Patterson B., Fields A.V., Shannon R.P. New insights into myocardial glucose metabolism: surviving under stress. Curr Opin Clin Nutr Metab Care 2009, 12:424-430.
52. Hishinuma S., Funamoto M., Fujio Y., Kunisada K., Yamauchi-Takihara K. Hypoxic stress induces cardiotrophin-1 expression in cardiac myocytes. Biochem Biophys Res Commun 1999, 264:436-440.
53. Krishnan J., Suter M., Windak R., Krebs T., Felley A., Montessuit C., et al. Activation of a HIF1α-PPARγ axis underlies the integration of glycolytic and lipid anabolic pathways in pathologic cardiac hypertrophy. Cell Metab 2009, 9:512-524.
54. Egert S., Nguyen N., Brosius F.C.I., Schwaiger M. Effects of wortmannin on insulin- and ischemia-induced stimulation of GLUT4 translocation and FDG uptake in perfused rat hearts. Cardiovasc Res 1997, 35:283-293.